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An ideal method for detecting RASs should cover current DAA targets NS3, NS5A, and NS5B for all genotypes, have a high analytical sensitivity, and be capable of detecting RASs in minority virus populations [8] . Amplification and sequencing of parts of the NS3 and NS5A has been used to detect RASs across multiple genotypes with high analytical sensitivity [9, 10] .
Alternatively, all RAS sites in HCV may be obtained within one amplicon with subtypespecific primers covering the entire ORF [11, 12] , subtype-specific primers with nested PCR generating a near full-length amplicon [13] , or pan-genotypic primers generating a near fulllength amplicon for multiple genotypes [14] . The advantage of the latter method is that prior knowledge of sample subtype is not required for amplification. Other methods have omitted the initial HCV specific amplification and used template-independent amplification [15] , direct RNA sequencing [16] , in combination with ribosomal RNA depletion [17] , or HCV probe based target enrichment [18] , but may display varying analytical sensitivity.
We adopted a strategy of generating a near full-length amplicon using pan-genotypic primers and subsequent next generation sequencing. Compared to the similar method A C C E P T E D M A N U S C R I P T published by Trémeaux et al. [14] , all steps have been optimized to increase sensitivity. The procedure provides in-depth RASs analysis, near full-length ORF consensus sequence and genotype simultaneously across multiple HCV genotypes, and it may therefore be used to replace standard HCV genotyping assays for primary characterization of specimens from chronically HCV infected individuals.
Objectives
Our aim was to develop a method that provides genotype and detection of resistanceassociated substitutions in NS3, NS5A, and NS5B of HCV without prior knowledge of sample genotype.
Study design

HCV Specimens
The cell culture derived HCV RNA sample TNcc contains a full-length subtype 1a genome [19] . Plasmids containing HCV strain specific whole genome sequences from isolates TN [19] , J6/JFH-1 [20] , DBN3acc [7] , SA13 [21, 22] and KH6a [21, 23] have been described previously.
Residual plasma from samples sent for routine genotyping were de-identified and stored at -20C prior to amplification. The treatment history of the patients was consequently unknown. A total of 101 samples from patients with HCV were included between January 4, 2016 and January 9, 2017 at the Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Copenhagen and included 10 different subtypes across 4 genotypes. Samples containing HCV subtypes other than 1a and 3a were preferentially included and samples with HCV subtypes 1a and 3a were selected to achieve a broad range of viral loads. Viral concentrations were 3.84-7.61 Log IU/mL (mean 5.99 Log IU/mL).
RNA extraction
RNA extraction was performed with the ZR Viral RNA kit (Zymo Research, Irvine, CA, USA) as previously described [17] with the modification that 300 µL sample was centrifuged at 1,500g for 10 minutes to pellet cell debris before 200 µL supernatant was used as input.
RT-PCR of near full-length open reading frame
Reverse transcription was performed with 12 µL template and 1 µL RNasin Plus RNase Inhibitor (Promega Corporation, Madison, WI, USA) with Maxima RT minus H reverse transcriptase (Thermo Fischer Scientific, Waltham, MA, USA) with 2.5 µM RTprimer oligo dA20 [24] at 40C for 2 hours. Reactions were inactivated at 85C for 5 minutes and placed on ice. Amplification was done in 4 replicates using Q5 Hot Start High-Fidelity 
PCR for characterization of subgenomic replicons
A sample containing subgenomic replicons were additionally amplified using alternative reverse primer NS2_R_3166 (Position in H77 3149-3166:
GGCCCTCACAAAGTATGG) in a three-step PCR with initial denaturation at 98C for 30 seconds, 35 cycles with 10 seconds denaturation at 98C, 10 seconds annealing at 65C and 1.5 minutes extension at 72C, with a final extension step at 72 C for 2 minutes.
Identification of RASs
A pipeline with software packages was developed to analyse the NGS data. Reads were excluded or trimmed with Sickle [26] to obtain reads with Phred quality scores ≥30.
Passing reads were assembled de novo with IVA [27] , mapped against the generated consensus sequence using BWA [28] , and SNP-calling was done using LoFreq SNP-caller [29] with a cut-off set at 1%. RAS analysis was performed with the author's own software
with a local, modified database extracted from Geno2Pheno [30] . Samples failing de novo assembly with IVA were handled by an iterative mapping strategy with BWA and subtype references [31] before SNP-calling.
Phylogenetic analysis was done using the assembled consensus sequences obtained. Sequences were aligned to reference subtypes [31] using MAFFT [32] .
Phylogenetic trees were constructed using PhyML [33] .
Structural genome variant analysis
All samples were screened for recombination with all available options in RDP4 [34] .
Samples were investigated for structural variants with LUMPY with standard settings [35] .
Results
Analytical sensitivity and inclusivity of long range RT-PCR
Analytical sensitivity was evaluated using low passage cell culture derived HCV TNcc RNA [19] for which all primers have a perfect match. This provides an estimate of maximally obtainable analytical sensitivity. Two 10-fold dilution series were prepared in parallel and tested in the RT-PCR in two replicates. All four reactions were amplified consistently down to the 10 -4 dilutions ( Figure 1 ). HCV RNA in the two 10 -4 dilutions were 3.87 Log IU/mL and 3.88 Log IU/mL, and provided a crude estimate of lower limit of amplification.
Samples with genotype 5 and 6 were not available as clinical samples. Instead plasmids SA13 and HK6a with 5a and 6a specific sequences were successfully amplified to evaluate inclusivity of these genotypes.
Assessment of assay generated nucleotide variation
The library preparation was evaluated with direct input of plasmids and amplicons of the plasmids TN, J6/JFH-1, DBN3acc, SA13, HK6a. All but one of the samples had less 
Validation on clinical samples
Of the 101 samples included, 94% (95/101) were successfully amplified and sequenced. The samples had the following genotype distribution 1a: 26/27, 1b: 14/15, 2b:
10/10, 3a: 27/27, 3b: 3/3, 3h: 1/1, 4a: 2/6, 4d: 10/10, 4o: 1/1, 4r: 1/1 (see supplementary   Table S1 ). Viral load ranged between 3.84-7.61 Log IU/mL (Figure 3 ). Successfully amplified samples had a mean coverage of 14,035 (277-57,732), and reading frames were open and encoded a single polyprotein. Recombinant sequences were not detected using RDP4.
The samples failing amplification were not strictly correlated to viral load (Figure 3 ).
Of the 6 samples failing amplification, 4 were of subtype 4a with a broad range of viral loads.
Two of these, sample 84 and 88, were amplified with subtype specific full-length open reading frame primers and both showed a mismatch in the reverse primer. A genotype 1a sample failing amplification, number 17, was also amplified with subtype specific primers and also had a mismatch in the reverse primer.
Reads from sample 46 assembled into two subtype 2b near full-length genomes 10% divergent at consensus level. Reads mapping to the two genomes were represented at a 3:2 ratio in favour of the genome designated 46.1. identified constitute subgenomic deletion variants as previously described [36] [37] [38] .
Phylogeny of the samples
Phylogeny of the near full-length genomes showed conformity to results from routine genotyping [39, 40] . 
Identification of RASs
The RAS pipeline identified all sites with nucleotide polymorphisms reported to convey resistance to any DAA, both polymorphisms naturally occurring as the most frequent 
Discussion
The aim of the present study was to develop a sequence based assay capable of identifying HCV genotype and the presence of RASs in clinical samples without prior characterization. Such an assay should be pan-genotypic, analytically sensitive, and capable to reproducibly identify RASs present in minority HCV populations. We successfully
sequenced clinical samples containing HCV genotype 1a, 1b, 2b, 3a, 3b, 3h, 4d, 4o, and 4r, however, the method failed to amplify 4/6 genotype 4a samples. In the study, rarer genotypes were prioritized to specifically test inclusivity. In our practise subtypes 1a, 1b, 2b, and 3a constitute 90% of genotyped samples, and genotype 4a constitutes 3%, although prevalence may be considerably higher in other regions [41, 42] .
The method successfully amplified clinical samples down to 3.84 Log IU/mL. Only 4% of samples for routine genotyping was below 4 Log IU/mL in a recent study from our institution [43] , and none was below this level in a study with 140 DAA treatment naïve patients [9] . The overall success rate of the method presented here is comparable to individual amplification of parts of NS3 and NS5A [9,10], and compares favourably with a previously reported almost full length amplification approach that obtained an overall amplification and sequencing success rate of 58% (19/33) [14] .
Three samples were analysed twice and the reproducibility across all sequenced sites were >99.5% at the consensus level. The frequency of extrinsic RASs only increased modestly by lowering the threshold for SNP calling and, interestingly, 7 of 8 RASs additionally identified were in NS5B. A recent analysis of data from clinical trials of genotype 1 patients treated with ledipasvir and sofosbuvir suggested that drug-specific RASs, i.e.
substitutions that emerged during drug treatment or conferring significantly reduced drug susceptibility in vitro, may impact treatment outcome in difficult to treat patient populations when present at baseline also at low frequencies [44] . Here, we detected NS5A substitutions Q30H and Y93H that are known to significantly reduce the efficacy of ledipasvir [44] .
Pre-treatment RAS testing is useful in selected patient populations [44] . The method 
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